Clinical trials: Lung Cancer Non-Small Cell Cancer (NSCLC)
Advanced Non-squamous NSCLC
A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC
The current study will compare the efficacy, safety, pharmacokinetics and immunogenicity of PF-06439535 (CN) in combination with paclitaxel and carboplatin versus bevacizumab sourced from the European Union (bevacizumab-EU) with…
- Trial name
- NCT04325698
- Testing
- PF-06439535 (CN), Bevacizumab-EU, Paclitaxel
- Where
- 4 sites in China
- Volunteers
- 8 people
- Sponsor
- Pfizer
NSCLC Stage IV, Metastatic Non-Small Cell Lung Cancer
Plasma-Adapted First-Line Pembro In NSCLC
This research study is studying to see if a blood test, collected at different times during the treatment of metastatic non-small lung cancer, can be used to detect early response in patients being treated with pembrolizumab and…
- Trial name
- NCT04166487
- Testing
- Pembrolizumab, PEMETREXED, CARBOPLATIN
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Julia K. Rotow, MD
Non-small Cell Lung Cancer
Clinical Application of MR-PET in Non-small Cell Lung Cancer: Diagnosis, Treatment Outcome, and Prognosis Prediction
It is a study that hypothesize that MR/PET can have better information than current CT image study, about the medical or surgical treatment outcome of lung cancer
- Trial name
- NCT03053804
- Testing
- MR/PET
- Where
- Taiwan
- Volunteers
- 75 people
- Sponsor
- National Taiwan University Hospital
Lung Cancer
Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00182806
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Roswell Park Cancer Institute
Advanced Non-small-cell Lung Cancer
Multimodality Treatment Including Curative Resection of Advanced NSCLC
This study retrospectively evaluates clinical parameters and outcome of patients with advanced stage non-small cell lung cancer treated with neoadjuvant therapy followed by curative-intent surgery at the Divison of Thoracic…
- Trial name
- NCT04455984
- Testing
- Date collection
- Where
- Austria
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Non-small Cell Lung Cancer
Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody
to evaluate the prognosis of non-small cell lung carcinoma patients under CIK cellular treatment with PD-1 blocking on top of the standard therapy
- Trial name
- NCT03282435
- Testing
- CIK cells with PD-1 blocking, standard lung cancer treament, CIK cells without PD-1 blocking
- Volunteers
- 30 people
- Sponsor
- Dalian University
Non-small Cell Lung Cancer
EGFR Mutation Detection From Advanced NSCLC Patient Tissue and Plasma in EGFR-TKI Treatment
This study has been designed in order to detect EGFR mutation abundance of tissue and concentration of plasma from Advanced Non-small Cell Lung Cancer during treatment with Tyrosine Kinase Inhibitor (TKI) .Through this experiment…
- Trial name
- NCT02644889
- Volunteers
- 100 people
- Sponsor
- GenoSaber
Non-Small Cell Lung Cancer (NSCLC), Hyperlipidemia
Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC
For Patients and Families Brief Title: Management of 1L Lorlatinib with Hyperlipidemia in ALK+ Advanced NSCLC What is this study about? This study is for people with ALK-positive non-small cell lung cancer (NSCLC) who are taking…
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Hyperlipidemia, ALK Gene Mutation, ALK-positive
- Trial name
- NCT07674524
- Testing
- For Part A - Observational Cohort:, Part B: Intensive Lipid-Lowering Group, For Part B - Intensive Group
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-sen University
Non-Small Cell Lung Cancer
Effect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy
The primary purpose of the study is to investigate if daily treatment with celecoxib, an inhibitor of cyclooxygenase-2, can prolong survival in patients with advanced non-small cell lung cancer who receive anticancer chemotherapy…
- Trial name
- CYCLUS (NCT00300729)
- Testing
- Celecoxib
- Where
- 13 sites in Sweden
- Volunteers
- 319 people
- Sponsor
- University Hospital, Linkoeping
Non Small Cell Lung Cancer
Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel
The purpose of this research study is to test the effectiveness of three treatment arms that are designed to improve survival in patients with non-small cell lung cancer.
- Trial name
- NCT02684461
- Testing
- Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non-Small Cell Lung Cancer
Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer
The goal of this clinical research study is to evaluate the effectiveness of Avastin® in combination with docetaxel and carboplatin in the treatment of lung cancer. The safety of this combination will also be studied.
- Trial name
- NCT00271505
- Testing
- Bevacizumab (Avastin), Carboplatin, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Small-Cell Lung Cancer
Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer
The primary objective is to estimate the time to progressive disease for patients who receive LY573636-sodium (hereafter referred to as LY573636) after two previous treatments for metastatic non-small cell lung cancer.
- Trial name
- NCT00363766
- Testing
- LY573636-sodium
- Where
- 7 sites in Germany, Italy
- Volunteers
- 52 people
- Sponsor
- Eli Lilly and Company
Lung Carcinoma, Lung Non-Small Cell Carcinoma
Using an Artificial Intelligence Software Tool (iSeg) During Radiation Treatment Planning for Patients With Lung Tumors
This clinical trial studies whether an artificial intelligence (AI) software tool called iSeg can be safely and effectively used during routine radiation treatment planning for patients with lung tumors.
- Conditions
- Lung Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Lung
- Trial name
- NCT07898241
- Testing
- Artificial Intelligence-based Intervention, Best Practice, Computed Tomography
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Northwestern University
Non-small Cell Lung Cancer
A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer
The purpose of the study is to evaluate safety and efficacy of WX-0593 oral tablets in ALK -positive, or ROS1-positive non-small cell lung cancer (NSCLC)
- Trial name
- NCT04641754
- Testing
- WX-0593 Tablets
- Where
- 41 sites in China
- Volunteers
- 176 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases
This is a prospective interventional study clinical study to investigate the efficacy and resistance mechanisms of intrathecal pemetrexed in patients with driver gene mutations advanced NSCLC with leptomeningeal metastases.
- Trial name
- EPIC (NCT06440954)
- Testing
- Intrathecal pemetrexed
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Hunan Province Tumor Hospital
Non-small Cell Lung Cancer
Efficacy Study of Comprehensive Rehabilitation Program Plus Chemotherapy in Postoperative NSCLC Patients
The investigators performed a multi-centered, randomized, placebo-controlled, prospective clinical trial on the effect of comprehensive rehabilitation program plus chemotherapy to improve quality of life(QOL) and long-term…
- Trial name
- NCT03372694
- Testing
- Rehabilitation Training, TCM, Rehabilitation Education
- Where
- China
- Volunteers
- 354 people
- Sponsor
- Shanghai University of Traditional Chinese Medicine
Non-Small Cell Lung Cancer
CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung Cancer
Lung cancer is the most common cancer worldwide, non-small cell lung cancer (NSCLC) comprises about 85% of all lung cancer cases, which is the leading cause of cancer mortality, and adenocarcinoma is the most prevalent subtype.
- Trial name
- NCT01871480
- Testing
- Group A:cytokine-induced killer cell +gefitinib, Group B:Gefitinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Kunming Medical University
Non-Small-Cell Lung
A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.
- Trial name
- MAP (NCT07316062)
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- AstraZeneca
Lung Cancer
Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue near the tumor.
- Trial name
- NCT00551369
- Testing
- SBRT
- Where
- 19 sites in United States
- Volunteers
- 33 people
- Sponsor
- Radiation Therapy Oncology Group
Psychosocial
Effects of Cancer Symptoms on Caregivers
The primary objectives are to: 1.1 identify and compare the experiences of minority and nonminority caregivers, including the prevalence and severity of physical (fatigue, sleep disturbance) and psychologic (depression, anxiety…
- Trial name
- NCT00351988
- Testing
- Phenomenological Interviews, Quantitative Interviews
- Where
- 4 sites in United States
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.